Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the complete response (no vomiting and no
need for other medications to treat nausea) in terminally ill patients suffering from nausea
and/or vomiting, who are treated with palonosetron. Another objective is to determine the
partial response (relief of nausea and vomiting to the extent that the patient wishes to
continue treatment with palonosetron) after being treated with palonosetron. Palonosetron is
currently approved by the FDA to prevent nausea and vomiting associated with chemotherapy.
The investigators are testing this medication to see if it can help to relieve nausea and
vomiting not associated with chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center